A NOVEL BUDESONIDE ORODISPERSIBLE TABLET WITH A SPECIAL ESOPHAGEAL-TARGETING CAN INDUCE COMPLETE CLINICAL, ENDOSCOPIC AND HISTOLOGIC REMISSION IN ACTIVE EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A POST-HOC ANALYSIS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EOS-1 TRIAL

Stephan Miehlke    

Conference
UEG Week 2019


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing